Singapore: Australia based Bionomics is recognized as the Innovative Asian Biotech of the Year at BioPharma Asia Industry Awards during the BioPharma Asia Convention, held in Singapore from March 10th to 13th.

BioPharma Asia Convention is Asia's largest biopharmaceutical event drawing almost 3,000 attendees from across the world with interests in biotech and pharmaceutical company partnering, industry trends and investment opportunities.

The citation underpinning the Innovative Asian Biotech of the Year award made reference to Bionomics' ability to adopt innovative technologies to develop novel drugs. It is also acknowledged the company's approach to drug development including the implementation of new processes, technologies or applications that achieve quantifiable and sustainable results.

Bionomics is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics has partnered with Merck & Co and Ironwood -Pharmaceuticals.